{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:35:46Z","timestamp":1790260546036,"version":"4.1.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":76,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.parkreldis.2013.02.006","type":"journal-article","created":{"date-parts":[[2013,2,27]],"date-time":"2013-02-27T19:48:24Z","timestamp":1361994504000},"page":"501-507","source":"Crossref","is-referenced-by-count":111,"title":["Peripheral neuropathy in Parkinson's disease: Levodopa exposure and implications for duodenal delivery"],"prefix":"10.1016","volume":"19","author":[{"given":"Thomas","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teus van","family":"Laar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Cornblath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Odin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Klostermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Grandas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Ebersbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter P.","family":"Urban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Valldeoriola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Antonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2013.02.006_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1212\/WNL.58.1.11","article-title":"Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"58","author":"Miyasaki","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib2","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1212\/01.wnl.0000215250.82576.87","article-title":"Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"66","author":"Pahwa","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib3","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1472-8206.1993.tb00238.x","article-title":"Pharmacokinetics of apomorphine in parkinsonian patients","volume":"7","author":"Nicolle","year":"1993","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib4","first-page":"579","article-title":"5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation","volume":"258","author":"Antonini","year":"2011","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib5","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1136\/jnnp.2005.078659","article-title":"Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus","volume":"77","author":"De Gaspari","year":"2006","journal-title":"Neurol Neurosurg Psychiatry"},{"issue":"Suppl.","key":"10.1016\/j.parkreldis.2013.02.006_bib6","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/j.parkreldis.2007.06.002","article-title":"Continuous dopaminergic stimulation\u2014from theory to clinical practice","volume":"13","author":"Antonini","year":"2007","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib7","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/mds.23524","article-title":"Comparison of subthalamic nucleus deep brain stimulation and duodopa in the treatment of advanced Parkinson's disease","volume":"26","author":"Merola","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib8","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1212\/01.WNL.0000149637.70961.4C","article-title":"Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease","volume":"64","author":"Nyholm","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib9","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1517\/14656566.8.5.657","article-title":"Duodenal levodopa infusion for the treatment of Parkinson's disease","volume":"8","author":"Samanta","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/WNF.0b013e3180ed449f","article-title":"Enteral levodopa\/carbidopa infusion in advanced Parkinson disease: long-term exposure","volume":"31","author":"Nyholm","year":"2008","journal-title":"Clin Neuropharmacol"},{"issue":"Suppl. 5","key":"10.1016\/j.parkreldis.2013.02.006_bib11","doi-asserted-by":"crossref","first-page":"S387","DOI":"10.1007\/s10072-008-1054-7","article-title":"Continuous dopaminergic stimulation achieved by duodenal levodopa infusion","volume":"29","author":"Odin","year":"2008","journal-title":"Neurol Sci"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib12","first-page":"935","article-title":"A\u00a0signal from the Italian pharmacovigilance database: levodopa\/carbidopa and polyneuropathy","volume":"33","author":"Capuano","year":"2010","journal-title":"Drug Saf"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib13","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/mds.22450","article-title":"Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease","volume":"24","author":"Devos","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib14","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00003088-200645020-00001","article-title":"Pharmacokinetic optimization in the treatment of Parkinson's disease: an update","volume":"45","author":"Nyholm","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib15","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/mds.22807","article-title":"Reversible encephalopathy and axonal neuropathy in Parkinson's disease during duodopa therapy","volume":"24","author":"Manca","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib16","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/mds.21500","article-title":"Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome","volume":"22","author":"Antonini","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib17","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1002\/mds.22137","article-title":"Neuropathy as a potential complication of levodopa use in Parkinson's disease","volume":"23","author":"Toth","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib18","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/ana.22021","article-title":"Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease","volume":"67","author":"Toth","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib19","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1600-0404.1992.tb04043.x","article-title":"Involvement of peripheral nervous system in juvenile Parkinson's disease","volume":"85","author":"Taly","year":"1992","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib20","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/brain\/awg142","article-title":"Parkin\u00a0disease: a phenotypic study of a large case series","volume":"126","author":"Khan","year":"2003","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib21","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/archneur.61.5.657","article-title":"Levodopa associated homocysteine increase and sural axonal neurodegeneration","volume":"61","author":"M\u00fcller","year":"2004","journal-title":"Arch Neurol"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib22","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1212\/01.wnl.0000171859.85078.3d","article-title":"Reduced amplitude of the sural nerve sensory action potential in PARK2 patients","volume":"65","author":"Ohsawa","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib23","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1093\/brain\/awn102","article-title":"Sensory deficit in Parkinson's disease: evidence of a cutaneous denervation","volume":"131","author":"Nolano","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib24","doi-asserted-by":"crossref","first-page":"59","DOI":"10.5507\/bp.2009.010","article-title":"Peripheral nerve involvement and severity of motor disorder in Parkinson's disease: a correlational study","volume":"153","author":"Chovancova","year":"2009","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib25","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/ana.22258","article-title":"A\u00a0case series of peripheral neuropathy in patients with Parkinson's disease","volume":"68","author":"Gondim Fde","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib26","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/mds.22878","article-title":"Neuropathy as a potential complication of levodopa use in Parkinson's disease: a pharmacological and pharmacovigilance point of view","volume":"25","author":"Montastruc","year":"2010","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib27","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/ana.22330","article-title":"Neuropathy in idiopathic Parkinson disease: an iatrogenic problem?","volume":"69","author":"Nolano","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib28","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1212\/WNL.0b013e31823a0ee4","article-title":"Neuropathy in Parkinson disease: prevalence and determinants","volume":"77","author":"Rajabally","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib29","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/mds.23760","article-title":"Has \u201clevodopa-induced neuropathy\u201d been reported in Parkinson's disease clinical trials?","volume":"26","author":"Teodoro","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib30","first-page":"1668","article-title":"Polyneuropathy while on duodenal levodopa infusion in Parkinson's disease patients: we must be alert","volume":"259","author":"Santos-Garc\u00eda","year":"2012","journal-title":"J\u00a0Neurol"},{"issue":"Suppl. 3","key":"10.1016\/j.parkreldis.2013.02.006_bib31","first-page":"S720","article-title":"Axonal polyneuropathy during duodenal levodopa treatment in a woman with idiopathic Parkinson's disease","volume":"25","author":"Gusmaroli","year":"2010","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib32","series-title":"Poster presentation at: 7th international congress on mental dysfunction and other non-motor features in Parkinson's disease","article-title":"Small fiber peripheral neuropathy presentation after starting treatment with continuous intraduodenal levodopa infusion in one patient with Parkinson disease","author":"Palas\u00ed","year":"2010"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib33","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1002\/mds.23342","article-title":"Subacute axonal neuropathy in Parkinson's disease with cobalamin and vitamin B6 deficiency under duodopa therapy","volume":"25","author":"Urban","year":"2010","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib34","doi-asserted-by":"crossref","first-page":"41","DOI":"10.33588\/rn.5101.2010363","article-title":"Intraduodenal infusion of levodopa","volume":"51","author":"Valldeoriola","year":"2010","journal-title":"Rev Neurol"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib35","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00702-011-0689-3","article-title":"Malnutritional neuropathy under intestinal levodopa infusion","volume":"119","author":"Klostermann","year":"2012","journal-title":"J\u00a0Neural Transm"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib36","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/mds.23408","article-title":"Transcutaneous port for continuous duodenal levodopa\/carbidopa administration in Parkinson's disease","volume":"26","author":"Meppelink","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib37","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/mds.23419","article-title":"Serum vitamin B(12) and folate levels in Parkinson's disease patients treated with duodenal levodopa infusion","volume":"26","author":"Santos-Garc\u00eda","year":"2011","journal-title":"Mov Disord"},{"issue":"Suppl. 3","key":"10.1016\/j.parkreldis.2013.02.006_bib38","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.1016\/S1353-8020(09)70821-1","article-title":"Emergencies in parkinsonism, akinetic crisis, life-threatening dyskinesias, and polyneuropathy during L-Dopa gel treatment","volume":"15","author":"Onofrj","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib39","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1212\/01.WNL.0000137886.74175.5A","article-title":"Homocysteine and levodopa: should Parkinson disease patients receive preventative therapy?","volume":"63","author":"Postuma","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib40","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archneur.61.5.633","article-title":"Levodopa elevates homocysteine. Is this a problem?","volume":"61","author":"O'Suilleabhain","year":"2004","journal-title":"Arch Neurol"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib41","first-page":"527","article-title":"Sulfate and cysteine levels in the plasma of patients with Parkinson's disease","volume":"16","author":"Allain","year":"1995","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib42","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000007984","article-title":"Elevated plasma levels of homocysteine in Parkinson's disease","volume":"40","author":"Kuhn","year":"1998","journal-title":"Eur Neurol"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib43","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0140-6736(99)01660-8","article-title":"Nigral endothelial dysfunction, homocysteine, and Parkinson's disease","volume":"354","author":"M\u00fcller","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib44","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1212\/WNL.55.3.437","article-title":"Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD","volume":"55","author":"Yasui","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib45","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1212\/WNL.56.2.281","article-title":"Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD","volume":"56","author":"Kuhn","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib46","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0304-3940(01)01972-3","article-title":"Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease","volume":"308","author":"M\u00fcller","year":"2001","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib47","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1212\/01.WNL.0000055899.24594.8E","article-title":"Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status","volume":"60","author":"Miller","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib48","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1136\/jnnp.74.4.549","article-title":"Benefit of folic acid supplementation in parkinsonian patients treated with levodopa","volume":"74","author":"M\u00fcller","year":"2003","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib49","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/mds.22879","article-title":"Reply: neuropathy as a potential complication of levodopa use in Parkinson's disease: a pharmacological and pharmacovigilance point of view","volume":"25","author":"Toth","year":"2010","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib50","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1046\/j.0022-3042.2001.00676.x","article-title":"Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease","volume":"80","author":"Duan","year":"2002","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib51","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00002826-199702000-00007","article-title":"Effect of L-Dopa and the catechol-O-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats","volume":"20","author":"Miller","year":"1997","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib52","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0076-6879(05)96014-X","article-title":"S-nitrosylation in Parkinson's disease and related neurodegenerative disorders","volume":"396","author":"Chung","year":"2005","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib53","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1586\/14737175.8.6.957","article-title":"Role of homocysteine in the treatment of Parkinson's disease","volume":"8","author":"M\u00fcller","year":"2008","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib54","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11239-011-0550-4","article-title":"Hyper-homocysteinemia: a novel risk factor or a powerful marker for cardiovascular diseases? Pathogenetic and therapeutical uncertainties","volume":"32","author":"Cacciapuoti","year":"2011","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib55","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/B978-0-12-381326-8.00004-1","article-title":"Catechol-O-methyltransferase enzyme: cofactor S-adenosyl-L-methionine and related mechanisms","volume":"95","author":"M\u00fcller","year":"2010","journal-title":"Int Rev Neurobiol"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib56","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/mds.22482","article-title":"Cysteine elevation in levodopa-treated patients with Parkinson's disease","volume":"24","author":"M\u00fcller","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib57","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1097\/01.chi.0000129220.04681.c1","article-title":"Neuropathy due to hypovitaminosis following excessive weight loss","volume":"43","author":"Heiser","year":"2004","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib58","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0891-8422(23)00366-X","article-title":"Nutritionally induced peripheral neuropathies","volume":"7","author":"Weber","year":"1990","journal-title":"Clin Podiatr Med Surg"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib59","unstructured":"Centers for Disease Control and Prevention. Managing patients with evidence of vitamin B12 deficiency. http:\/\/www.cdc.gov\/ncbddd\/b12\/patients.html. Last updated 29.06.09. [accessed 12.03.12]."},{"key":"10.1016\/j.parkreldis.2013.02.006_bib60","first-page":"680","article-title":"Causes and early diagnosis of vitamin B12 deficiency","volume":"105","author":"Hermann","year":"2008","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib61","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/fampra\/cml008","article-title":"Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency: a systematic review of randomized controlled trials","volume":"23","author":"Butler","year":"2006","journal-title":"Fam Pract"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib62","first-page":"CD004655","article-title":"Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency","volume":"3","author":"Vidal-Alaball","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib63","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00228-006-0132-0","article-title":"Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients","volume":"62","author":"M\u00fcller","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.parkreldis.2013.02.006_bib64","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1468-1331.2011.03614.x","article-title":"Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial","volume":"19","author":"Nyholm","year":"2012","journal-title":"Eur J Neurol"}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802013000734?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802013000734?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T22:20:05Z","timestamp":1745965205000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802013000734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":64,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S1353802013000734"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2013.02.006","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}